Search Results - "Orbegoso, Cecilia"

Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity by Heindl, Andreas, Khan, Adnan Mujahid, Rodrigues, Daniel Nava, Eason, Katherine, Sadanandam, Anguraj, Orbegoso, Cecilia, Punta, Marco, Sottoriva, Andrea, Lise, Stefano, Banerjee, Susana, Yuan, Yinyin

“…How tumor microenvironmental forces shape plasticity of cancer cell morphology is poorly understood. Here, we conduct automated histology image and spatial…”
Get full text

Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer by Flood, Emuella, Krasnow, Anna, Orbegoso, Cecilia, Karantzoulis, Stella, Bailey, Julie, Bayet, Solène, Elghouayel, Arthur, Foxley, Andrew, Sommavilla, Roberto, Schiavon, Gaia

“…Designing clinical trials with the emphasis on the patient-centered approach and focusing on clinical outcomes that are meaningful to patients is viewed as a…”
Get full text

Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms by Saini, Kamal S, de Las Heras, Begoña, Plummer, Ruth, Moreno, Victor, Romano, Marco, de Castro, Javier, Aftimos, Philippe, Fredriksson, Judy, Bhattacharyya, Gouri Shankar, Olivo, Martin Sebastian, Schiavon, Gaia, Punie, Kevin, Garcia-Foncillas, Jesus, Rogata, Ernesto, Pfeiffer, Richie, Orbegoso, Cecilia, Morrison, Kenneth, Curigliano, Giuseppe, Chin, Lynda, Saini, Monika Lamba, Rekdal, Øystein, Anderson, Steven, Cortes, Javier, Leone, Manuela, Dancey, Janet, Twelves, Chris, Awada, Ahmad

Get full text

The current status of immunotherapy for cervical cancer by Orbegoso, Cecilia, Murali, Krithika, Banerjee, Susana

“…Immunotherapy has been proven effective in several tumours, hence diverse immune checkpoint inhibitors are currently licensed for the treatment of melanoma,…”
Get full text

The role of Cediranib in ovarian cancer by Orbegoso, Cecilia, Marquina, Gloria, George, Angela, Banerjee, Susana

“…Treatment options for relapsed ovarian cancer have increased over the decade with the addition of targeted agents, such as PARP inhibitors and antiangiogenic…”
Get more information

Prevalence and clinical implications of mismatch repair (MMR) deficiency in unselected non-serous epithelial ovarian cancer (EOC) patients (pts) by Scaranti, Mariana, Murali, Krithika, Orbegoso, Cecilia, Vroobel, Katherine, Banerjee, Susana N., Gore, Martin Eric, Attygalle, Ayoma, George, Angela

“…Abstract only 1521 Background: It has previously been reported that 6-7% of clear cell (CC) and endometrioid (E) ovarian cancers are MMR deficient (MMRd). The…”
Get full text

Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 by Modi, Shanu, Niikura, Naoki, Yamashita, Toshinari, Jacot, William, Sohn, Joohyuk, Tokunaga, Eriko, Vidal, Maria Jesus, Park, Yeon Hee, Lee, Keun Seok, Chae, Yeesoo, Ueno, Naoto T., Prat, Aleix, Suto, Fumitaka, Kuwahara, Yusuke, McEwen, Robert, Feng, Wenqin, Goto, Hiroki, Orbegoso, Cecilia, Cameron, David A., Tsurutani, Junji

“…1020 Background: DESTINY-Breast04 (NCT03734029) showed improved progression-free survival (PFS) and overall survival for T-DXd vs TPC in pts with HER2-low (IHC…”
Get full text

Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial by Morgan, Robert D., Banerjee, Susana, Hall, Marcia, Clamp, Andrew R., Zhou, Cong, Hasan, Jurjees, Orbegoso, Cecilia, Taylor, Sarah, Tugwood, Jonathan, Lyon, Alexander R., Dive, Caroline, Rustin, Gordon J.S., Jayson, Gordon C.

“…Vascular co-option is a resistance mechanism to anti-angiogenic agents, but combinations of anti-vascular agents may overcome this resistance. We report a…”
Get full text

Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study by Yamashita, Toshinari, Sohn, Joo Hyuk, Tokunaga, Eriko, Niikura, Naoki, Park, Yeon Hee, Lee, Keun Seok, Chae, Yee Soo, Xu, Binghe, Wang, Xiaojia, Im, Seock-Ah, Li, Wei, Lu, Yen-Shen, Aguilar, Cecilia Orbegoso, Nishijima, Soichiro, Nishiyama, Yuji, Sugihara, Masahiro, Modi, Shanu, Tsurutani, Junji

“…Background In the global phase 3 DESTINY-Breast04 study (NCT03734029), the anti-human epidermal growth factor 2 (HER2) antibody–drug conjugate trastuzumab…”
Get full text

OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel+/- novel agents in platinum-resistant ovarian cancer—Vistusertib (AZD2014) by Banerjee, Susana N., Lewsley, Liz-Anne, Clamp, Andrew R., Gabra, Hani, Herbertson, Rebecca, Green, Clare, Orbegoso, Cecilia, Wilson, Cheryl, Banerji, Udai, Hanif, Aishah, McNeish, Iain A., Paul, James

“…Abstract only TPS5609 Background: There is an urgent need to improve outcomes for patients with platinum-resistant and refractory ovarian cancer (PROC)…”
Get full text

Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers by Sebbagh, Sihem, Roux, Julia, Dreyer, Chantal, Neuzillet, Cindy, de Gramont, Armand, Orbegoso, Cecilia, Hentic, Olivia, Hammel, Pascal, de Gramont, Aimery, Raymond, Eric, André, Thierry, Chibaudel, Benoist, Faivre, Sandrine

“…Gemcitabine (GEM)-platinum chemotherapy stands as first-line therapy for patients with recurrent/advanced biliary tract cancer (BTC), yielding progression-free…”
Get more information